New indication for Tyverb

Tyverb (lapatinib) has had its licence extended to include use in combination with an aromatase inhibitor (AI), for the first-line treatment of post-menopausal women with hormone receptor (HR)-positive, ErbB2 (HER2)-overexpressing metastatic breast cancer for whom chemotherapy is not currently intended.

The registration trial showed that there was a significant improvement in progression-free survival (PFS) in patients overexpressing ErbB2 when both ErbB2 and HR receptors were targeted with lapatinib in combination with letrozole (an AI), with patients given lapatinib plus letrozole experiencing a median PFS of 8.2 months and patients given placebo plus letrozole experiencing a median PFS of 3 months.

View Tyverb drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases